This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Glenn S. Gerber, MD; Ian M. Thompson, MD; Ronald Thisted, PhD; Gerald W. Chodak, MD
University of Chicago (Ill)

JAMA. 1993;270(11):1315-1316.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—We agree with the comments of Drs Maloney and Green. Certainly, the true efficacy of screening requires a demonstration of a reduction in disease-specific mortality. A variety of factors, such as lead-time and length-time biases, as well as possible overdetection of prostate cancer, may falsely suggest benefit from screening when none truly exists. While the National Cancer Institute is undertaking a randomized, prospective trial to study this issue, results will not be available for approximately 16 years. In the meantime, physicians must make their best judgment regarding prostate cancer screening: who should be screened and when and how? In light of recent studies from Europe regarding the excellent 10-year survival of men with well- to moderately differentiated tumors treated by observation and/or palliative therapy alone,¹ it seems reasonable to limit screening to men with at least a 10-year life expectancy. In addition, since the true efficacy of . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?